Business Standard

Aurobindo Pharma declines 6% on USFDA warning letter for Dayton facility

The company said it would engage with the regulator and would try to resolve the issue at the earliest

Aurobindo Pharma
Premium

Aurobindo Pharma

SI Reporter Mumbai
Shares of Aurobindo Pharma were down 6 per cent to Rs 755 on the BSE on Thursday after the company's arm has received a warning letter from the US health regulator for its oral solid manufacturing facility situated at Dayton, New Jersey. In comparison, the S&P BSE Sensex was down 0.34 per cent at 40,567 points at 10:40 am.

"The AuroLife Pharma LLC, a wholly owned stepdown subsidiary of the Company, has received a warning letter from the US Food and Drug Administration (USFDA) for its oral solid manufacturing facility situated at Dayton, New Jersey," Aurobindo Pharma said in exchange filing.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 22 2020 | 10:41 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com